AI Analysis
AI-generated analysis. Always verify with the original filing.
MIRA Pharmaceuticals reported preclinical data showing Mira-55 produced no THC- or rimonabant-associated CNS side effects, including no psychogenic effects, sedation, catalepsy, motor impairment, or anxiogenic effects at oral doses of 10, 30, and 100 mg/kg. These results build on prior morphine-comparable pain relief in inflammatory pain models without opioid risks, supporting planned IND submission for inflammatory pain.
Key Takeaways
1Mira-55 evaluated in hypothermia, catalepsy, Elevated Plus Maze, and Open Field assays
2No cannabinoid-like psychogenic effects at 10, 30, or 100 mg/kg doses
3Dose-dependent increase in time spent in open arms of Elevated Plus Maze, indicating reduced anxiety-like behavior
4Comparable to vehicle controls in Open Field testing, unlike anxiogenic rimonabant
5Previously demonstrated morphine-comparable analgesic effects in validated inflammatory pain model without opioid risks
6Advancing Mira-55 toward IND submission for inflammatory pain